高级检索
当前位置: 首页 > 详情页

Study of Platinum Plus Etoposide With or Without BGB-A317 in Participants With Untreated Extensive-Stage Small Cell Lung Cancer

文献详情

编号/登记号:
研究开始时间:
研究结束时间:
项目类型:
本院角色:
多中心研究:
招募状态:
试验分期:
研究类型:
研究参与人:
研究单位: [1]Jilin Provincial Tumor Hospital [2]BeiGene [3]The Second Hospital of Anhui Medical University,Hefei,Anhui,China,230601 [4]Beijing Hospital,Beijing,Beijing,China,100005 [5]China-Japan Friendship Hospital,Beijing,Beijing,China,100029 [6]Chinese PLA General Hospital,Beijing,Beijing,China,100039 [7]The Third Hospital of Peking University,Beijing,Beijing,China,100191 [8]Peking Union Medical College Hospital, Chinese Academy of Medical Sciences,Beijing,Beijing,China,100730 [9]Name:Peking University International Hospital,Beijing,Beijing,China,102206 [10]Beijing Cancer Hospital,Beijing,Beijing,China [11]Army Special Medical Center (Daping Hospital),Chongqing,Chongqing,China,400042 [12]Fujian Cancer Hospital,Fuzhou,Fujian,China,350014 [13]Fujian Medical University Union Hospital,Fuzhou,Fujian,China,361003 [14]First Affiliated Hospital of Xiamen University,Xiamen,Fujian,China,361003 [15]First Hospital of Lanzhou University,Lanzhou,Gansu,China,730000 [16]Cancer Center of Guangzhou Medical University,Guangzhou,Guangdong,China,510059 [17]The First Affiliated Hospital of Guangzhou Medical University,Guangzhou,Guangdong,China,510059 [18]Guangdong Provincial People's Hospital,Guangzhou,Guangdong,China,510080 [19]Affiliated Hospital of Guilin Medical University,Guilin,Guangxi,China,541001 [20]Guangxi Zhuang Autonomous Region People''s Hospital,Nanning,Guangxi,China,168600 [21]Affiliated Tumor Hospital of Guangxi Medical University,Nanning,Guangxi,China,530021 [22]Affiliated Tumor Hospital of Harbin Medical University,Harbin,Heilongjiang,China,150081 [23]Henan Cancer Hospital,Zhengzhou,Henan,China,450008 [24]First Affiliated Hospital of Zhengzhou University,Zhengzhou,Henan,China,450052 [25]Tongji Hospital Tongji Medical College Huazhong University of Sciences and Technology,Wuhan,Hubei,China,430000 [26]Union Hospital Tongji Medical College Huazhong University of Sciences and Technology,Wuhan,Hubei,China,430000 [27]The Central Hospital Wuhan,Wuhan,Hubei,China,430014 [28]Hunan Cancer Hospital,Changsha,Hunan,China,410006 [29]Xiangya Hospital, Central South University,Changsha,Hunan,China,410008 [30]Changsha Central Hospital,Changsha,Hunan,China,410018 [31]General Hospital of Nanjing Military Command,Nanjing,Jiangsu,China,210002 [32]Nanjing Chest Hospital,Nanjing,Jiangsu,China,210029 [33]The First Affiliated Hospital of Soochow University,Suzhou,Jiangsu,China,215006 [34]Jilin Cancer Hospital,Changchun,Jilin,China,130012 [35]The First Affiliated Hospital of China Medical University,Shenyang,Liaoning,China,110001 [36]Liaoning Cancer Hospital,Shenyang,Liaoning,China,110042 [37]Jinan Central Hospital,Jinan,Shandong,China,250013 [38]Shandong Cancer Hospital,Jinan,Shandong,China,250117 [39]Affiliated hospital of Qingdao University,Qingdao,Shandong,China,266003 [40]Yantai Yuhuangding Hospital,Yantai,Shandong,China,264000 [41]Shanghai Chest Hospital,Shanghai,Shanghai,China,200030 [42]Shanghai Pulmonary Hospital,Shanghai,Shanghai,China,200433 [43]Shannxi Provincial Cancer Hospital,Xi''an,Shannxi,China,710061 [44]The First Affiliated Hospital of Xi ''an Jiaotong University,Xi''an,Shannxi,China,710061 [45]West China Hospital · Sichuan University,Chengdu,Sichuan,China,610041 [46]Sichuan Cancer Hospital,Chengdu,Sichuan,China,610042 [47]Tianjin Cancer Hospital,Tianjin,Tianjin,China,300060 [48]General Hospital of Tianjin Medical University,Tianjin,Tianjin,China,300070 [49]Affiliated Tumor Hospital of Xinjiang Medical University,Ürümqi,Xinjiang,China,830000 [50]Yunnan Cancer Hospital,Kunming,Yunnan,China,650118 [51]The First Affiliated Hospital of Zhejiang University Medical College,Hangzhou,Zhejiang,China,310003 [52]Zhejiang Cancer Hospital,Hangzhou,Zhejiang,China,310022

研究目的:
This is a randomized, double-blind, placebo-controlled, multicenter, Phase 3 study to compare the efficacy of tislelizumab + cisplatin or carboplatin + etoposide (Arm A) and placebo + cisplatin or carboplatin + etoposide (Arm B) as first-line treatment in approximately 455 participants who have previously untreated extensive-stage small cell lung cancer (ES-SCLC)

资源点击量:52808 今日访问量:0 总访问量:4561 更新日期:2025-01-01 建议使用谷歌、火狐浏览器 常见问题

版权所有©2020 四川省肿瘤医院 技术支持:重庆聚合科技有限公司 地址:成都市人民南路四段55号